Published in Gene Therapy Weekly, November 2nd, 2000
The data reported were gathered from in vitro and in vivo studies and outline the improved transduction efficacy that can be achieved using replicative and semi-replicative vector systems compared to defective vectors. The results prompt careful reconsideration of using replicative viruses for treating cancer, Avax Technologies says.
The studies were supported by Pierre et Marie Curie University, Paris, France, and Centre National de la...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.